Contigen
PreclinicalSmall molecule
Contigen is one of 23 small molecule programs targeting Stress urinary incontinence. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Stress Urinary Incontinence
#DrugCompanyPhaseTrials
1Cymbalta
Alnylam PharmaceuticalsPhase 3
Tofranil
SanofiPhase 3
Quietus
Merck & Co.Phase 3
Foundayo
Eli LillyPhase 3
Liposomal Bupivacaine
TTLC Biopharmaceuticals, Inc.
Approved
Duloxetine HCL
Eli LillyApproved
Toviaz
PfizerPhase 2
Platelet Rich Plasma
ZZagazig University
Phase 3
Depo-Testosterone
AAzurity Pharmaceuticals
Phase 2
Platelet Rich Fibrin
GGovernment Dental College and Research Institute, Bangalore
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Contigen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SStanford University